1. Home
  2. INBK vs IMUX Comparison

INBK vs IMUX Comparison

Compare INBK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Internet Bancorp

INBK

First Internet Bancorp

HOLD

Current Price

$23.81

Market Cap

179.3M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$9.61

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INBK
IMUX
Founded
1999
2016
Country
United States
United States
Employees
355
66
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.3M
152.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
INBK
IMUX
Price
$23.81
$9.61
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$23.25
$36.00
AVG Volume (30 Days)
50.7K
2.4M
Earning Date
04-30-2026
05-14-2026
Dividend Yield
1.06%
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$279.34
N/A
Revenue Next Year
$12.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.05
$0.51
52 Week High
$28.51
$10.91

Technical Indicators

Market Signals
Indicator
INBK
IMUX
Relative Strength Index (RSI) 61.60 85.13
Support Level $23.52 $0.75
Resistance Level $24.85 N/A
Average True Range (ATR) 0.94 0.46
MACD -0.08 1.01
Stochastic Oscillator 61.69 87.07

Price Performance

Historical Comparison
INBK
IMUX

About INBK First Internet Bancorp

First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: